Waiting times for kidney transplants exceed 3 to 5 years in many parts of the United States.
1 Yet more than 500 high-quality kidneys from deceased donors with hepatitis C virus (HCV) infection are discarded annually.
2,3 Direct-acting antiviral agents, which are associated with high HCV cure rates and manageable side effects, have created the potential to substantially increase the number of kidney transplants by making HCV-infected kidneys available to HCV-negative candidates on the waiting list.
4,5